CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
CA19-9 kinetics during systemic chemotherapy in patients with advanced or recurrent biliary tract cancer.
复制标题
晚期或复发性胆道癌患者全身化疗期间的 CA19-9 动力学。
DOI：
10.1007/s00280-017-3456-9
复制
发表时间：
2017
期刊：
影响因子：
--
通讯作者：
Koike K.
中科院分区：
文献类型：
--
作者：
Takahara N;Nakai Y;Isayama H;Sasaki T;Saito K;Noguchi K;Suzuki T;Nakamura T;Sato T;Ishigaki K;Hakuta R;Takeda T;Uchino R;Mizuno S;Kogure H;Tada M;Koike K.
PurposeThe role of carbohydrate antigen 19-9（CA19-9）kinetics in patients with biliary tract cancer（BTC）receiving chemotherapy may be discussed.MethodsA total 185 advanced or recurrent BTC patients receiving a first line chemotherapy between January 2006 and March 2016，were retrospectively studied.分别于化疗前和化疗2周期后测定血清CA 19 -9水平，根据CA 19 -9应答情况分为CA 19 -9下降组（下降≥ 30%）、稳定组（下降< 30%且上升< 20%）和上升组（上升≥ 20%）。CA 19 -9反应与放射学肿瘤反应、无进展生存期（PFS）和总生存期（OS）的关系进行了研究。根据CA 19 -9缓解，三组之间的中位PFS和OS显著不同：CA 19 -9降低、稳定和升高组的PFS分别为8.0、5.7和3.5个月（p< 0.001），CA 19 -9降低、稳定和升高组的OS分别为18.8、16.0和7.5个月（p< 0.001）。多因素分析显示，CA 19 -9反应是预测OS和PFS的重要因素，此外，基线时CA 19 -9反应和体力状态也是预测OS和PFS的重要因素。结论一线化疗前2个周期后CA 19 -9反应是预测晚期和复发性BTC患者OS和PFS的重要因素。
PurposeThe role of carbohydrate antigen 19-9 (CA19-9) kinetics in patients with biliary tract cancer (BTC) receiving chemotherapy remains to be elucidated.MethodsA total of 185 advanced or recurrent BTC patients receiving a first line chemotherapy between January 2006 and March 2016, were retrospectively studied. Serum CA19-9 was measured at baseline and after two cycles of chemotherapy, and patients were categorized based on CA19-9 response: CA19-9 decrease group (≥ 30% decrease), stable group (< 30% decrease and < 20% increase) and increase group (≥ 20% increase). The associations of CA19-9 response with radiological tumor response, progression-free survival (PFS) and overall survival (OS) were investigated.ResultsThere was a statistically significant association between CA19-9 response and radiological tumor responses (p< 0.001). The median PFS and OS were significantly different among three groups according to CA19-9 response: PFS of 8.0, 5.7 and 3.5 months in CA19-9 decrease, stable and increase groups (p< 0.001) and OS of 18.8, 16.0 and 7.5 months in CA19-9 decrease, stable and increase groups, respectively (p< 0.001). Multivariate analyses showed that CA19-9 response was prognostic both of OS and PFS in addition, to CA19-9 at baseline, and performance status.ConclusionCA19-9 kinetics after the first two cycles of a first line chemotherapy was a prognostic factor for OS and PFS in patients with advanced and recurrent BTC.